Navigation Links
New ways to treat solid tumors
Date:8/15/2014

An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumour effects.

As EphA3 is present in normal organs only during embryonic development but is expressed in blood cancers and in solid tumours, this antibody-based approach may be a suitable candidate treatment for solid tumours.

The researchers from Monash University and Ludwig Cancer Research, in Australia, and KaloBios Pharmaceuticals, in the US, have had their findings published in the journal Cancer Research.

The team, led jointly by the late Professor Martin Lackmann, from the School of Biomedical Sciences at Monash; and Professor Andrew Scott, from Ludwig Cancer Research, has found that even if tumour cells do not have this molecule they can thrive by recruiting and taking advantage of supporting EphA3-containing cells in the tumour micro-environment.

First author, Dr Mary Vail, Monash Department of Biochemistry and Molecular Biology said: "The tumour cells send out signals to the surrounding area and say: 'We need a blood supply and a foundation upon which to spread'."

"We have shown that EphA3 expressing stromal stem cells, which are produced by the bone marrow, form cells that support and create blood vessels in tumours," Dr Vail said.

Professor Andrew Scott's team at Ludwig introduced human prostate cancer cells into a mouse model to mimic disease progression in humans. EphA3 was found in stromal cells and blood vessels surrounding the tumour.

They also observed that treatment with an antibody against EphA3 (chIIIA4) significantly slowed tumour growth. The antibody damaged tumour blood vessels and disrupted the stromal micro-environment, and cancer cells died because their 'life-support' was compromised.

"In addition, we screened various tumours from patient biopsies - sarcomas, melanomas as well as prostate, colon, brea
'/>"/>

Contact: Rachael Fergusson
rachael.fergusson@monash.edu
61-399-034-841
Monash University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
4. Study Suggests Treating Dyslexia Before Kids Learn to Read
5. Rapid Asthma Treatment in ER May Prevent Admission
6. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
7. Breast cancer patients suffer treatment-related side effects long after completing care
8. Mayo Clinic offers newly approved treatment for acid reflux disease
9. Mobile Stroke Units Might Trim Time to Treatment
10. Breast Cancer Treatment Side Effects May Last for Years
11. Study Shows New Option for Kids With Tough-to-Treat Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... , scheduled for October 27-29, 2015 in San Jose, CA. The first ... primarily focus on the void that exists where battery development and energy storage ...
(Date:8/27/2015)... ... 2015 , ... More destinations and stores are becoming pet-friendly, making the family ... sharing some tips to help your whole family travel safely and comfortably. , According ... each year. Amica is sharing the following tips from the American Society for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... blending all in one machine with the Nutri Ninja® Auto-iQ Pro Complete and ... Auto-iQ™ Smooth Boost™ Technology that takes drink customization to a whole new level. ...
(Date:8/27/2015)... ... 2015 , ... King Kullen, America’s First Supermarket, is celebrating 85 years of ... 1930 and recognized by the Smithsonian Institute as America’s First Supermarket, King Kullen changed ... Cullen & Kennedy families have created a culture of caring while building their business. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... development solutions for drugs, biologics and consumer health products, today announced that Ms. ... FlyPharma Conference, to be held at the Radisson Blu Edwardian Hotel, London Heathrow, ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2
... NEW YORK, Jan. 29 MS -- Cold and ... adults and children each year, according to,the Centers for ... can lead,to complications, especially in children and the elderly. ... be given within two days,of the infection,s onset., ...
... OAK BROOK, Ill. A novel treatment for blood clots ... to a pilot study published in the February issue of ... with a fiber-binding thrombolytic agent effectively treats deep vein thrombosis ... , This treatment regimen is able to clear blood clots ...
... New reports released,today by the Kaiser Family Foundation,s Commission ... states in the past year and,a half to expand ... may be curtailed as a deteriorating economic climate and ... in the economy, the federal failure to reauthorize the ...
... 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ... groups across the United States, today announced its,preliminary, ... 31,2007. Results are subject to completion of the ... Results, The company expects to report 2007 ...
... Reminding People to Properly Care for Both their Body ,Engine, and Vehicle ... ... 28 Jiffy Lube today announces its,first-ever, nationwide cause-related campaign to support ... help eradicate,heart disease. Throughout February and March, 1,823 Jiffy Lube service,centers, more ...
... researchers is the first to conduct a genome-wide study ... to DNA mutations, which are implicated in cancer and ... of biology Kateryna Makova, the group investigated the simultaneous ... the susceptibility to mutations of microsatellites -- variable-length sequences ...
Cached Medicine News:Health News:Flu and Fever Detection Facts for Dr. Mom 2Health News:Flu and Fever Detection Facts for Dr. Mom 3Health News:New therapy effectively treats deep vein thrombosis 2Health News:States Promoted Broader Coverage for Children in 2007, But Report That a Declining Economy Coupled With Lack of SCHIP Reauthorization and New Federal Rules Now Compromise Efforts to Reduce the Number of Uninsured 2Health News:States Promoted Broader Coverage for Children in 2007, But Report That a Declining Economy Coupled With Lack of SCHIP Reauthorization and New Federal Rules Now Compromise Efforts to Reduce the Number of Uninsured 3Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results 3Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 2Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 3Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 4Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 5Health News:Scientists explore factors contributing to DNA mutations 2Health News:Scientists explore factors contributing to DNA mutations 3Health News:Scientists explore factors contributing to DNA mutations 4
(Date:8/27/2015)... 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ) ... the Morgan Stanley Global Healthcare Conference on September 16, ... invited to listen to the live discussion via the ... at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay ... the conclusion of the live event and accessible via ...
(Date:8/27/2015)... The nation,s newest Actos trial gets underway Thursday, August 27 ... courtroom.  Attorneys representing two southern Nevada ... after using the diabetes drug Actos. "Takeda Pharmaceuticals ... that their drug Actos caused an increased risk of bladder ... hold Takeda responsible it is appropriate to seek substantial punitive ...
(Date:8/27/2015)...  Mytrus, a technology and services company revolutionizing clinical trials, announced ... has received approval for use by Britain,s ... first time e-Consent technology will be used in a ... Mytrus was also the first electronic informed consent ... the U.S. Food and Drug Administration in 2011. It ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... , SAN DIEGO, Oct. 26 Horizon Therapeutics, ... an analysis from two pivotal Phase 3 trials ... HZT-501, a combination of ibuprofen with high-dose famotidine. ... risk factors for the development of non-steroidal anti-inflammatory ...
... Volcano Corporation (Nasdaq: VOLC ), a leader in ... and treatment of coronary and peripheral artery disease, today announced ... quarter and first nine months of fiscal 2009 on Thursday, ... to discuss its financial results and operating activities open to ...
Cached Medicine Technology:Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 2Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 3Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 4Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
... Medpor Channel Implants, designed to ... the surgeon with an excellent ... wall and floor blowout defects. ... for placement of one or ...
The new Medpor Superior Lateral Orbital Rim is designed for subtle augmentation of the lateral and superior or orbital rims in patients who are hypoplasic in the superior-lateral aspect of the orbita...
The new Medpor Orbital Rim Onlay Implants are designed to support the lower eyelid and lateral canthus in patients who have inadequate support due to congenital variation or changes with aging....
... handle. Divides nucleus for phacoemulsification. Nuclear division ... hardness can be pre-chopped with pre-chop forceps ... fragments is rapid. Risk of rupturing posterior ... sound time and minimal movement of phaco ...
Medicine Products: